Cargando…

Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer

The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies be...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Camille, Mansour, Ali, Ismailova, Aiten, Sarmadi, Fatemeh, Scarlata, David A., Bouttier, Manuella, Zeitouni, Camille, Wang, Catherine, Gleason, James L., White, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038752/
https://www.ncbi.nlm.nih.gov/pubmed/35468986
http://dx.doi.org/10.1038/s41598-022-10740-9
_version_ 1784693972205043712
author Barbier, Camille
Mansour, Ali
Ismailova, Aiten
Sarmadi, Fatemeh
Scarlata, David A.
Bouttier, Manuella
Zeitouni, Camille
Wang, Catherine
Gleason, James L.
White, John H.
author_facet Barbier, Camille
Mansour, Ali
Ismailova, Aiten
Sarmadi, Fatemeh
Scarlata, David A.
Bouttier, Manuella
Zeitouni, Camille
Wang, Catherine
Gleason, James L.
White, John H.
author_sort Barbier, Camille
collection PubMed
description The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies because they exhibit synergistic activities with other anticancer agents such as histone deacetylase inhibitors (HDACi). We have developed a series of hybrid molecules that combine HDACi within the backbone of a VDR agonist and thus represent fully integrated bifunctional molecules. They exhibit anti-tumor efficacy in reducing tumor growth and metastases in an aggressive model of triple-negative breast cancer. However, their solubility is limited by their hydrophobic diarylpentane cores. Our goals here were two-fold: (1) to improve the solubility of hybrids by introducing nitrogen into diarylpentane cores, and (2) to investigate the molecular mechanisms underlying their anti-tumor efficacy by performing comparative gene expression profiling studies with 1,25D and the potent HDACi suberoylanilide hydroxamic acid (SAHA). We found that substituting aryl with pyrydyl rings did not sacrifice bifunctionality and modestly improved solubility. Notably, one compound, AM-193, displayed enhanced potency as a VDR agonist and in cellular assays of cytotoxicity. RNAseq studies in triple negative breast cancer cells revealed that gene expression profiles of hybrids were very similar to that of 1,25D, as was that observed with 1,25D and SAHA combined. The effects of SAHA alone on gene expression were limited and distinct from those 1,25D or hybrids. The combined results suggest that efficacy of hybrids arises from targeting HDACs that do not have a direct role in gene regulation. Moreover, pathways analysis revealed that hybrids regulate numerous genes controlling immune cell infiltration into tumors and suppress the expression of several secreted molecules that promote breast cancer growth and metastasis.
format Online
Article
Text
id pubmed-9038752
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90387522022-04-27 Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer Barbier, Camille Mansour, Ali Ismailova, Aiten Sarmadi, Fatemeh Scarlata, David A. Bouttier, Manuella Zeitouni, Camille Wang, Catherine Gleason, James L. White, John H. Sci Rep Article The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies because they exhibit synergistic activities with other anticancer agents such as histone deacetylase inhibitors (HDACi). We have developed a series of hybrid molecules that combine HDACi within the backbone of a VDR agonist and thus represent fully integrated bifunctional molecules. They exhibit anti-tumor efficacy in reducing tumor growth and metastases in an aggressive model of triple-negative breast cancer. However, their solubility is limited by their hydrophobic diarylpentane cores. Our goals here were two-fold: (1) to improve the solubility of hybrids by introducing nitrogen into diarylpentane cores, and (2) to investigate the molecular mechanisms underlying their anti-tumor efficacy by performing comparative gene expression profiling studies with 1,25D and the potent HDACi suberoylanilide hydroxamic acid (SAHA). We found that substituting aryl with pyrydyl rings did not sacrifice bifunctionality and modestly improved solubility. Notably, one compound, AM-193, displayed enhanced potency as a VDR agonist and in cellular assays of cytotoxicity. RNAseq studies in triple negative breast cancer cells revealed that gene expression profiles of hybrids were very similar to that of 1,25D, as was that observed with 1,25D and SAHA combined. The effects of SAHA alone on gene expression were limited and distinct from those 1,25D or hybrids. The combined results suggest that efficacy of hybrids arises from targeting HDACs that do not have a direct role in gene regulation. Moreover, pathways analysis revealed that hybrids regulate numerous genes controlling immune cell infiltration into tumors and suppress the expression of several secreted molecules that promote breast cancer growth and metastasis. Nature Publishing Group UK 2022-04-25 /pmc/articles/PMC9038752/ /pubmed/35468986 http://dx.doi.org/10.1038/s41598-022-10740-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Barbier, Camille
Mansour, Ali
Ismailova, Aiten
Sarmadi, Fatemeh
Scarlata, David A.
Bouttier, Manuella
Zeitouni, Camille
Wang, Catherine
Gleason, James L.
White, John H.
Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title_full Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title_fullStr Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title_full_unstemmed Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title_short Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
title_sort molecular mechanisms of bifunctional vitamin d receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038752/
https://www.ncbi.nlm.nih.gov/pubmed/35468986
http://dx.doi.org/10.1038/s41598-022-10740-9
work_keys_str_mv AT barbiercamille molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT mansourali molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT ismailovaaiten molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT sarmadifatemeh molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT scarlatadavida molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT bouttiermanuella molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT zeitounicamille molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT wangcatherine molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT gleasonjamesl molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer
AT whitejohnh molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer